Quick Order Cart

Cat. No. ARG43821

DNM1L Knockout THP-1 Cell Line

  • Product Type:

    In Stock Cell Lines

  • Species:

    Homo sapiens (Human)

  • Tissue Source:

    Blood (peripheral blood)

  • Disease:

    Acute monoblastic leukemia

The DNM1L Knockout THP-1 Cell Line is a CRISPR/Cas9-edited knockout cell line derived from the human monocytic leukemia THP-1 line, widely used to model monocyte and macrophage functions. It enables loss-of-function studies of DNM1L, which encodes the mitochondrial fission GTPase DRP1, a key regulator of mitochondrial dynamics and apoptosis. Knockout of DNM1L impairs DRP1-mediated fission, leading to elongated mitochondrial networks and altered apoptotic sensitivity. This model is ideal for investigating mitochondrial dynamics, macrophage polarization, and pathways involving interacting factors such as Fis1 and Mff, with applications in neurodegeneration, cancer, and drug target validation.

Inquire Now

In stock

Ships next business day


Ask a Question

Shipping Info:

Cryopreserved in vials and shipped on dry ice


Disclaimer:

For Research Use Only

  • Characteristics

    Host Cell

    THP-1

    Sex of Donor

    Male

    Age

    1 year

    Derived From Site

    In situ; Peripheral blood

    Gene Name

    DNM1L

    Gene Identifier

    NCBI Gene ID 10059

    Growth Mode

    Suspension

    Storage

    Liquid nitrogen (LN2)

  • Culture Conditions

    Temperature

    37°C

    Atmosphere

    5% CO₂

  • Quality Control

    Sterility testing

    The bacterial, yeast, and fungi are not detected in these cells by daily monitor.

    Mycoplasma testing

    Negative for mycoplasma through PCR analysis

  • Disclaimer

    Intended Use

    This product is intended for laboratory in vitro use only. lt is not intended for diagnostic, therapeutic, or clinical applications.

    Disclaimer

    Ascent Research endeavors to provide accurate and up-to-date product information. However, no warranties or representations are made regarding its completeness or reliability. References to scientific literature and patents are for informational purposes only, and the customer assumes sole responsibility for verifying their accuracy.

    By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use, including compliance with all applicable safety and environmental regulations and precautions. Relevant laws, regulations, and ethical guidelines must be followed in conducting any research, modifications, or derivatives derived from this product.

    This product is provided "AS IS", and except as expressly stated herein, Ascent Research disclaims all other warranties, express or implied. Under no circumstances shall Ascent Research, its affiliates, or representatives be liable for indirect, incidental, consequential, or punitive damages arising from the use of this material. While Ascent Research employs rigorous quality control measures, we shall not be held responsible for damages resulting from misidentification or misinterpretation of the provided materials.

Description

The DNM1L Knockout THP-1 Cell Line is a CRISPR/Cas9-edited knockout cell line designed to disrupt the DNM1L gene in the human monocytic leukemia cell line THP-1. This cell line serves as a robust loss-of-function model for investigating the roles of dynamin-related protein 1 (DRP1) in mitochondrial dynamics, apoptosis, and macrophage-related functions. The knockout product format is a stable cell line, providing a consistent genetic background for reproducible experimental outcomes without requiring transient manipulations.

THP-1 cells were originally derived from the peripheral blood of a 1-year-old male patient with acute monocytic leukemia and are widely adopted as a model system for monocyte and macrophage biology. These cells can be differentiated into macrophage-like cells, enabling studies on phagocytosis, cytokine production, and cellular differentiation. Their genetic tractability and relevance to human myeloid lineage make them a valuable host for gene editing, particularly for dissecting pathways involved in innate immunity and metabolic regulation.

DNM1L encodes the large GTPase DRP1, which oligomerizes around mitochondria to constrict and sever membranes, thereby promoting mitochondrial and peroxisomal fission. DRP1 activity is tightly regulated by upstream kinases and phosphatases such as CDK1, PKA, CaMKII, calcineurin, and AMPK, and it is modulated by ubiquitination via MARCH5. Upon activation, DRP1 translocates to the mitochondrial surface and interacts with adaptor proteins Fis1, Mff, MiD49, and MiD51 to execute fission. Downstream, DRP1-mediated fragmentation influences cytochrome c release, caspase activation, and reactive oxygen species production, linking mitochondrial morphology to apoptotic signaling. Disruption of DNM1L leads to elongated mitochondrial networks and altered apoptosis sensitivity, making this knockout line a critical tool for dissecting the molecular interplay between mitochondrial dynamics and cell fate decisions.

In the THP-1 macrophage context, DNM1L knockout provides a physiologically relevant platform to explore how mitochondrial fission impacts immune cell functions. Macrophage polarization, phagocytic capacity, and inflammatory responses are energetically demanding processes that rely on mitochondrial remodeling. The loss of DRP1 may impair mitochondrial quality control and mitophagy, potentially altering macrophage differentiation and function. This model is thus instrumental for studying the role of mitochondrial dynamics in disorders linked to dysregulated macrophage activity, including neurodegenerative diseases (Alzheimer??s and Parkinson??s), cardiomyopathies, and cancer, where DRP1-mediated fission is often perturbed.

Researchers can employ the DNM1L Knockout THP-1 Cell Line in a diverse array of experimental applications. It is well-suited for investigating mitochondrial fission mechanisms, apoptotic regulation, and macrophage polarization under normal and pathological conditions. Typical assays include western blotting for DRP1 and its interacting partners, immunofluorescence and MitoTracker staining to visualize mitochondrial morphology, flow cytometry to assess mitochondrial mass, apoptosis assays (caspase activity and Annexin V staining), co-immunoprecipitation to study protein interactions, and Seahorse metabolic flux analysis to evaluate bioenergetic changes. This cell line also supports drug target validation and cancer cell metabolism studies, especially those involving DRP1 inhibitors or modulators of mitochondrial dynamics. For additional information or technical support, please contact Ascent Research.

Reset Password

    Reach Us Questions? Click Me Here!

    Fill out the form below and a member of our team will contact you shortly!

    *Required field



      Reach Us

      Fill out the form below and a member of our team will contact you shortly!

      *Required field

      Product Inquiry (Optional)